Davidson, Michael H.

Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control

Ray, K. K., Ginsberg, H. N., Davidson, M. H., Pordy, R., Bessac, L., Minini, P., Eckel, R. H., & Cannon, C. P. (2016) · Circulation

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 127

Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD

Koren, M. J., Davidson, M. H., Wilson, D. J., Fayyad, R. S., Zuckerman, A., & Reed, D. P. (2009) · American Journal of Kidney Diseases

Lipoproteins and Cardiovascular HealthBlood Pressure and Hypertension Studies

Cited by 115

Statin safety: an appraisal from the adverse event reporting system

Davidson, M. H., Clark, J. A., Glass, L. M., & Kanumalla, A. (2006) · The American Journal of Cardiology

Pharmacovigilance and Adverse Drug ReactionsLipoproteins and Cardiovascular Health

Cited by 113

A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial)

Maki, K. C., Orloff, D. G., Nicholls, S. J., Dunbar, R. L., Roth, E. M., Curcio, D., Johnson, J., Kling, D., & Davidson, M. H. (2013) · Clinical Therapeutics

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 104

Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study

Offman, E., Marenco, T., Ferber, S., Johnson, J., Kling, D., Curcio, D., & Davidson, M. (2013) · Vascular Health and Risk Management

Fatty Acid Research and HealthAquaculture Nutrition and Growth

Cited by 92

Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia

Skulas-Ray, A. C., West, S. G., Davidson, M. H., & Kris-Etherton, P. M. (2008) · Expert Opinion on Pharmacotherapy

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 91

Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease

Gotto, A. M., Cannon, C. P., Li, X. S., Vaidya, S., Kher, U., Brinton, E. A., Davidson, M., Moon, J. E., Shah, S., Dansky, H. M., et al. (2014) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 86

Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin

Rader, D. J., Davidson, M. H., Caplan, R. J., & Pears, J. S. (2003) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 84

The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study

Davidson, M., Stevenson, M., Hsieh, A., Ahmad, Z., Roeters van Lennep, J., Crowson, C., & Witztum, J. L. (2018) · Journal of Clinical Lipidology

Lipid metabolism and disordersLymphatic Disorders and Treatments

Cited by 82

Rosuvastatin safety: lessons from the FDA review and post-approval surveillance

Davidson, M. H. (2004) · Expert Opinion on Drug Safety

Lipoproteins and Cardiovascular HealthPharmacovigilance and Adverse Drug Reactions

Cited by 80

Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial

Nissen, S. E., Lincoff, A. M., Wolski, K., Ballantyne, C. M., Kastelein, J. J. P., Ridker, P. M., Ray, K. K., McGuire, D. K., Mozaffarian, D., Koenig, W., et al. (2021) · JAMA Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 76

Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia

Davidson, M. H., Maki, K. C., Bays, H., Carter, R., & Ballantyne, C. M. (2009) · Journal of Clinical Lipidology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 71

Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: pooled analysis of alirocumab phase 3 trials

Ray, K. K., Vallejo-Vaz, A. J., Ginsberg, H. N., Davidson, M. H., Louie, M. J., Bujas-Bobanovic, M., Minini, P., Eckel, R. H., & Cannon, C. P. (2019) · Atherosclerosis

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 69

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia

Grundy, S. M., Arai, H., Barter, P., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A., Davidson, M. H., Genest, J., Kesäniemi, Y. A., et al. (2014) · Atherosclerosis

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 68

Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial.

Davidson, M. H., Maki, K. C., Kalkowski, J., Schaefer, E. J., Torri, S. A., & Drennan, K. B. (1997) · Journal of the American College of Nutrition

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 68

Religious education and midlife observance are associated with dementia three decades later in Israeli men

Beeri, M. S., Davidson, M., Silverman, J. M., Schmeidler, J., Springer, R. R., Noy, S., & Goldbourt, U. (2008) · Journal of Clinical Epidemiology

Dementia and Cognitive Impairment ResearchReligion, Spirituality, and Psychology

Cited by 65

Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia

Maki, K. C., Guyton, J. R., Orringer, C. E., Hamilton-Craig, I., Alexander, D. D., & Davidson, M. H. (2016) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 62

Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib

Davidson, M., Liu, S. X., Barter, P., Brinton, E. A., Cannon, C. P., Gotto, A. M., Leary, E. T., Shah, S., Stepanavage, M., Mitchel, Y., et al. (2013) · Journal of Lipid Research

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 56

The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study

Davidson, M., Stevenson, M., Hsieh, A., Ahmad, Z., Crowson, C., & Witztum, J. L. (2017) · Expert Review of Cardiovascular Therapy

Lipid metabolism and disordersLymphatic Disorders and Treatments

Cited by 54

Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial

Dunbar, R. L., Nicholls, S. J., Maki, K. C., Roth, E. M., Orloff, D. G., Curcio, D., Johnson, J., Kling, D., & Davidson, M. H. (2015) · Lipids in Health and Disease

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 52

Incorporation of lean red meat into a National Cholesterol Education Program Step I diet: a long-term, randomized clinical trial in free-living persons with hypercholesterolemia.

Hunninghake, D. B., Maki, K. C., Kwiterovich, P. O., Davidson, M. H., Dicklin, M. R., & Kafonek, S. D. (2000) · Journal of the American College of Nutrition

Nutritional Studies and DietLipoproteins and Cardiovascular Health

Cited by 52

Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects

Davidson, M. H., Bays, H. E., Stein, E., Maki, K. C., Shalwitz, R. A., & Doyle, R. (2006) · Clinical Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 51

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial

Stroes, E. S. G., Susekov, A. V., de Bruin, T. W. A., Kvarnström, M., Yang, H., & Davidson, M. H. (2018) · Journal of Clinical Lipidology

Fatty Acid Research and HealthLipid metabolism and disorders

Cited by 38

Cardiorenal Safety of OTC Analgesics

White, W. B., Kloner, R. A., Angiolillo, D. J., & Davidson, M. H. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics

Inflammatory mediators and NSAID effectsPharmacovigilance and Adverse Drug Reactions

Cited by 31